In this systematic review and meta-analysis, we established the incidence of MYC/BCL2 co-expression in all de novo DLBCL studies published to date and calculated pooled estimates of double expressor status according to different IHC cutoff values. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.